



SOME INDUSTRIAL  
CHEMICAL INTERMEDIATES  
AND SOLVENTS

VOLUME 125

This publication represents the views and expert  
opinions of an IARC Working Group on the  
Identification of Carcinogenic Hazards to Humans,  
which met in Lyon, 5–11 November 2019

LYON, FRANCE - 2020

IARC MONOGRAPHS  
ON THE IDENTIFICATION  
OF CARCINOGENIC HAZARDS  
TO HUMANS

# CONTENTS

---

<b>NOTE TO THE READER .....</b>	<b>1</b>
<b>LIST OF PARTICIPANTS .....</b>	<b>3</b>
<b>PREAMBLE .....</b>	<b>7</b>
A. GENERAL PRINCIPLES AND PROCEDURES .....	7
1. Background .....	7
2. Objective and scope .....	8
3. Selection of agents for review .....	9
4. The Working Group and other meeting participants .....	9
5. Working procedures .....	11
6. Overview of the scientific review and evaluation process .....	12
7. Responsibilities of the Working Group .....	14
B. SCIENTIFIC REVIEW AND EVALUATION .....	15
1. Exposure characterization .....	15
2. Studies of cancer in humans .....	18
3. Studies of cancer in experimental animals .....	23
4. Mechanistic evidence .....	26
5. Summary of data reported .....	29
6. Evaluation and rationale .....	30
References .....	35
<b>GENERAL REMARKS .....</b>	<b>39</b>
<b>ALLYL CHLORIDE .....</b>	<b>43</b>
1. Exposure Characterization .....	43
1.1 Identification of the agent .....	43
1.2 Production and uses .....	44
1.3 Methods of measurement and analysis .....	44
1.4 Occurrence and Exposure .....	46
1.5 Regulations and guidelines .....	46
2. Cancer in Humans .....	50

---

3. Cancer in Experimental Animals .....	51
3.1 Mouse .....	51
3.2 Rat .....	59
4. Mechanistic Evidence .....	60
4.1 Absorption, distribution, metabolism, and excretion .....	60
4.2 Evidence relevant to key characteristics of carcinogens .....	61
4.3 Data relevant to comparisons across agents and end-points .....	67
5. Summary of Data Reported .....	68
5.1 Exposure characterization .....	68
5.2 Cancer in humans .....	68
5.3 Cancer in experimental animals .....	68
5.4 Mechanistic evidence .....	69
6. Evaluation and Rationale .....	69
6.1 Cancer in humans .....	69
6.2 Cancer in experimental animals .....	69
6.3 Mechanistic evidence .....	69
6.4 Overall evaluation .....	69
6.5 Rationale .....	69
References .....	70
 <b>1-BROMO-3-CHLOROPROPANE .....</b>	 <b>75</b>
1. Exposure Characterization .....	75
1.1 Identification of the agent .....	75
1.2 Production and uses .....	76
1.3 Methods of measurement and analysis .....	76
1.4 Occurrence and exposure .....	77
1.5 Regulations and guidelines .....	77
2. Cancer in Humans .....	77
3. Cancer in Experimental Animals .....	78
3.1 Mouse .....	78
3.2 Rat .....	84
4. Mechanistic Evidence .....	86
4.1 Absorption, distribution, metabolism, and excretion .....	86
4.2 Evidence relevant to key characteristics of carcinogens .....	86
5. Summary of Data Reported .....	90
5.1 Exposure characterization .....	90
5.2 Cancer in humans .....	90
5.3 Cancer in experimental animals .....	90
5.4 Mechanistic evidence .....	90
6. Evaluation and Rationale .....	91
6.1 Cancer in humans .....	91
6.2 Cancer in experimental animals .....	91
6.3 Mechanistic evidence .....	91
6.4 Overall evaluation .....	91
6.5 Rationale .....	91
References .....	91

---

<b>1-BUTYL GLYCIDYL ETHER.....</b>	<b>95</b>
1. Exposure Characterization .....	95
1.1 Identification of the agent .....	95
1.2 Production and uses.....	96
1.3 Methods of measurement and analysis .....	96
1.4 Occurrence and exposure.....	97
1.5 Regulations and guidelines .....	99
2. Cancer in Humans .....	99
3. Cancer in Experimental Animals .....	99
3.1 Mouse .....	99
3.2 Rat .....	102
4. Mechanistic Evidence.....	103
4.1 Absorption, distribution, metabolism, and excretion .....	103
4.2 Evidence relevant to key characteristics of carcinogens.....	105
4.3 Data relevant to comparisons across agents and end-points .....	112
5. Summary of Data Reported .....	113
5.1 Exposure characterization .....	113
5.2 Cancer in humans.....	113
5.3 Cancer in experimental animals.....	113
5.4 Mechanistic evidence .....	114
6. Evaluation and Rationale.....	114
6.1 Cancer in humans.....	114
6.2 Cancer in experimental animals.....	114
6.3 Mechanistic evidence .....	115
6.4 Overall evaluation .....	115
6.5 Rationale .....	115
References.....	115
<b>4-CHLOROBENZOTRIFLUORIDE.....</b>	<b>119</b>
1. Exposure Characterization .....	119
1.1 Identification of the agent .....	119
1.2 Production and uses.....	120
1.3 Methods of measurement and analysis .....	120
1.4 Occurrence and exposure.....	121
1.5 Regulations and guidelines .....	123
2. Cancer in Humans .....	123
3. Cancer in Experimental Animals .....	123
3.1 Mouse .....	123
3.2 Rat .....	127
4. Mechanistic Evidence.....	128
4.1 Absorption, distribution, metabolism, and excretion .....	128
4.2 Evidence relevant to key characteristics of carcinogens.....	130
4.3 Other relevant evidence .....	135
4.4 Data relevant to comparisons across agents and end-points .....	135

5. Summary of Data Reported .....	136
5.1 Exposure data .....	136
5.2 Cancer in humans .....	136
5.3 Cancer in experimental animals .....	136
5.4 Mechanistic evidence .....	137
6. Evaluation and Rationale .....	137
6.1 Cancer in humans .....	137
6.2 Cancer in experimental animals .....	137
6.3 Mechanistic evidence .....	137
6.4 Overall evaluation .....	137
6.5 Rationale .....	137
References .....	137
<b>GLYCIDYL METHACRYLATE .....</b>	<b>143</b>
1. Exposure Characterization .....	143
1.1 Identification of the agent .....	143
1.2 Production and use .....	144
1.3 Methods of measurement and analysis .....	145
1.4 Exposure and occurrence .....	145
1.5 Regulations and guidelines .....	147
2. Cancer in Humans .....	147
3. Cancer in Experimental Animals .....	147
3.1 Mouse .....	147
3.2 Rat .....	151
4. Mechanistic Evidence .....	153
4.1 Absorption, distribution, metabolism, and excretion .....	153
4.2 Evidence relevant to key characteristics of carcinogens .....	154
4.3 Data relevant to comparisons across agents and end-points .....	166
5. Summary of Data Reported .....	167
5.1 Exposure characterization .....	167
5.2 Cancer in humans .....	167
5.3 Cancer in experimental animals .....	167
5.4 Mechanistic evidence .....	168
6. Evaluation and Rationale .....	169
6.1 Cancer in humans .....	169
6.2 Cancer in experimental animals .....	169
6.3 Mechanistic evidence .....	169
6.4 Overall evaluation .....	169
6.5 Rationale .....	169
References .....	170
<b>LIST OF ABBREVIATIONS .....</b>	<b>177</b>